Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.45 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | SRC | P12931 | 2/20 | 0.39 |
| ▸ | BRAF | P15056 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6096869 | 0.89 | POLB (0.51) | POLBSMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL6096303 | 0.86 | CYP1A2 (0.45) | POLBSMN1; SMN2NPC1RAB9APTGS2 | |
| SCHEMBL6098508 | 0.86 | POLB (0.53) | POLBSMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL6096343 | 0.81 | POLB (0.46) | POLBSMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL6097893 | 0.78 | TAAR1 (0.43) | POLBSMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL6097954 | 0.74 | PTGS2 (0.41) | POLBSMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL6098136 | 0.74 | CYP2C19 (0.42) | POLBPTGS2PTGS1ALDH1A1CYP2C9 | |
| SCHEMBL6097275 | 0.73 | PTGS1 (0.70) | PTGS2PTGS1CYP2C9 | |
| SCHEMBL6176854 | 0.73 | POLB (0.53) | POLBSMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL13300321 | 0.73 | POLB (0.64) | POLBSMN1; SMN2NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7001917-B2 | Pyrazole compounds as anti-inflammatory and analgesic agents | WARNER LAMBERT COMPANY LLC (US) | 2006-02-21 | — | — | US | disclosed |
| EP-1495005-A1 | PYRAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | Pfizer Japan Inc. (JP) | 2005-01-12 | — | — | EP | disclosed |
| US-20040019045-A1 | 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents | HIRANO MISATO (JP) | 2004-01-29 | — | — | US | disclosed |
| WO-2003087061-A1 | PYRAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER JAPAN INC. (JP) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019045-A1 | 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents | PTGER1, PTGS1, PTGIR | POLB 4327/4885SMN1; SMN2 4491/4885NPC1 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.